Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

Inclusion Criteria

• •Surgical or biopsy-proven diagnosis of WHO grade 3 AA.
• •1. Gd-contrast lesion margins are not clearly defined,
• •2. Gd-contrast lesions are only measurable in one dimension,
• •3. Gd-contrast lesion has two perpendicular diameters less than 10 mm,
• •4. Gd-contrast lesion has two perpendicular diameters greater than 10 mm but less than 20 mm and lesion does not demonstrate central necrosis,
• •5. Recent histopathological confirmation of WHO grade 3 AA
• •Received EBRT and temozolomide chemotherapy prior to first tumor progression or recurrence of WHO Grade 3 AA.
• •Completion of EBRT ≥ 6 months prior to randomization.
• •Karnofsky Performance Status (KPS) score of ≥ 70.